Molecular Partners AG Gross Profit

The latest gross profit for MOLN is $-10M as of June 2026. That compares with $680K in the prior-year period — down 1563.8% year over year. That is below the Healthcare sector average of $67B. Investors often review this figure alongside Molecular Partners AG's historical trend and sector peers before judging valuation or financial health.

Over the past year, MOLN's gross profit moved from $680K to $-10M — a 1563.8% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Molecular Partners AG's operating scale or balance-sheet position.

Against Healthcare companies, MOLN currently prints $-10M for gross profit, while the sector average sits near $67B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Molecular Partners AG's growth, margins, and balance sheet.

A gross profit figure of $-10M for MOLN is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $67B. Explore the charts below for those layers of context.

After noting MOLN's gross profit ($-10M), review year-over-year change from $680K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.